Panbela Therapeutics Inc expected to post a loss of $4.70 a share - Earnings Preview

Panbela Therapeutics

09/08/2023 03:04

* Panbela Therapeutics Inc  PBLA.OQ   PBLA.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 10. 
    * 
    * ​Refinitiv's mean analyst estimate for Panbela
Therapeutics Inc
is for a loss of $4.70 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Panbela
Therapeutics Inc is $31​, above​ its last closing price
of $1.84. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -15.76      -16.10     -19.50    Missed  -21.1
 Dec. 31 2023  -1.14       -1.11      -1.70     Missed  -53.3
               hundred     hundred    hundred           
 Sep. 30 2022              -2.64      -2.52     Beat    4.5​
                           hundred    hundred           
 Jun. 30 2022  -3.04       -3.04      -1.81     Missed  -496.1
               hundred     hundred    thousand          
 ​​Mar.        -3.05       -3.06      -3.24     Missed  -5.9
 31 2022       hundred     hundred    hundred           
 Dec. 31 2021  -2.28       -2.16      -3.12     Missed  -44.4​
               hundred     hundred    hundred           
 Sep. 30 2021              -2.76      -1.92     Beat    30.4
                           hundred    hundred           
 Jun. 30 2021  -2.60       -2.12      -2.64     Missed  -24.5
               hundred     hundred    hundred           
 This summary was machine generated August 9 at 02:04 GMT.  All
figures in US dollars  unless otherwise stated